WuXi TIDES has developed high loading solid-phase PMO synthesis process that can achieve >50% yield, >75% crude purity, >90% final product purity with <0.045 EU/mg endotoxin. Read more
Peptide Conjugate Discovery
Home | Services & Solutions | Peptide | Discovery Synthesis | Conjugate
Peptide conjugation is a rapidly expanding field, offering a new modality for targeted drug delivery. This approach enhances efficacy and reduces side effects in cancer treatment. Our comprehensive peptide platform, combined with our small molecule chemistry capability, provides a one-stop solution for your peptide conjugate discovery projects.
Experience Highlight:
- We support various peptide conjugates : Toxin, Metal, GalNAc, PMO, Oligonucleotide, Radionuclide Drug Conjugate(RDC), etc.
- 2,000+ discovery stage projects delivered
- 350+ linkers synthesized
- 50+ payload modification supported
Samples of Peptide Conjugates
Case Study: Bicyclic Peptide Conjugation
We facilitate seamless collaboration among SPPS, LPPS, purification, and analytical teams, all located at one site.
We offer an accelerated delivery time of 3-4 weeks, a significant improvement over the conventional approaches that involve separate manufacturing of peptides and payloads.
Seamless collaboration with in-parallel activities among 4 workstreams
Swift sample transport and information sharing from upstream to downstream teams
Peptide-Phosphorodiamidate Morpholino Oligomers (PMO)
As a type of oligonucleotide molecule, Phosphorodiamidate Morpholino Oligomers (PMO) are short single-stranded DNA analogs that are built upon a backbone of morpholine rings connected by phosphorodiamidate linkages. They are routinely used for gene silencing and the recently developed PMO-based drugs as excellent antisense reagents, however the synthesis of PMO remains challenging.
Related Resources
Webinar: Challenges and Opportunities in Peptide Drug Conjugates (PDCs)
Empowering Highly Potent Peptide Drug Conjugate Scale-up with Flow Chemistry
